Kornimate/medical-research-clean huggingface dataset:
study of the efficacy and tolerance of light therapy in sensitive skin

Conditions: Sensitive Skin

Summary: light-emitting diode (led) light therapy is increasingly used successfully and without adverse effects in diabetic leg ulcer, chronic low back pain, chronic myofacial pain in the neck and in several dermatoses such as acne, psoriasis, alopecia areata and skin rejuvenation. a korean study conducted in 2013 suggested its effectiveness in patients with sensitive skin in connection with rosacea, acne, eczema. the objective of the study is to perform a study in subjects with a sensitive skin without associated dermatosis.

the objective of the study is to evaluate the efficacy of light-emitting diode therapy in subjects with sensitive skin and to assess pain improvement, evaluation of improvement in pruritus and evaluation of treatment tolerance.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * age less than or equal to 70 * sensitive skin defined by a score ≥ 40 on the sensiscale scale * patient able to consent exclusion criteria: * persons under 18 years of age or over. * persons suffering from disorders of higher functions preventing comprehension of the questionnaire. * pregnancy. * analgesic or medication acting on the nervous system. * other dermatosis of the face (example: rosacea, seborrheic dermatitis, acne ...). * neurological or psychiatric illness. * a photosensitizing drug. * refusal of patient * patients under legal protection
feasibility of a first-line physical activity intervention after stroke

Conditions: Stroke; Ischemic Stroke; Hemorrhagic Stroke

Summary: the goal of this study is to explore a new intervention that supports physical activity within the first 6 weeks after stroke. all participants will complete assessments at weeks 0 and 7. during weeks 1 through 6, participants will use a fitbit inspire to track their step counts and meet with an occupational therapist one time per week. they will also complete weekly surveys. physical activity levels will be measured using surveys and a wearable activpal monitor 6 times during the study: weeks 1, 3, 5, 7, 12, and 24.


Eligibility criteria:
inclusion criteria: * stroke diagnosis confirmed by imaging * admitted to fairview health system (minnesota) at the time of study enrollment or discharged to a community-based setting from fairview health system within 10 days before study enrollment * able and willing to participate fully in the study and provide informed consent or proxy consent with participant assent exclusion criteria: * discharge anticipated to a transitional care unit, skilled nursing facility, or other non-community-based care setting * severe cognitive or communication impairments (inability to respond accurately to complete study screening questions or to provide informed consent or assent * comorbid neurological disorder (parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, alzheimer's disease, huntington's disease, glioblastoma, spinal cord injury, cerebral palsy) * comorbid cancer, currently undergoing chemotherapy or radiation treatment * received inpatient treatment or was hospitalized for psychiatric condition and/or alcohol or substance abuse within the past 12 months * current diagnosis of a terimnal illness and/or receiving hospice care * history of allergic reaction to adhesives that precludes the use of an adhesive necessary for adherence to activpal measurement * inability to speak, read, or understand english * concurrent participation in another rehabilitation intervention research study * resides more than 50 miles outside of the twin cities metropolitan area * investigator discretion for safety or adherence reasons

Keywords: physical activity occupational therapy behavioral intervention stroke rehabilitation
effect of sildenafil for sustained pah after mv surgery (superior trial)

Conditions: Hypertension, Pulmonary; Diseases of Mitral Valve

Summary: the purpose of this study is to determine whether sildenafil is effective in the treatment of sustained pulmonary artery hypertension after corrected mitral valve disease.


Eligibility criteria:
inclusion criteria: * new york heart association functional class (nyha fc) ≥ 2 dyspnea which was sustained till one year after the previous mitral valve surgery (repair or replacement) * tr vmax ≥ 3.5m/s by echocardiography * normal left ventricle ejection fraction (ef ≥ 50%) * pulmonary vascular resistance ≥ 3 wood unit or diastolic pressure gradient ≥ 7mmhg by cardiac catheterization exclusion criteria: * other valve disease more than moderate degree (ex. aortic stenosis, aortic regurgitation) * liver cirrhosis * chronic renal failure with serum creatinine ≥ 1.7mg/dl * lung disease (ex. chronic obstructive pulmonary disease, asthma) * thyroid dysfunction * other causes which can lead to pulmonary hypertension
acute nutritional ketosis in gsd iiia

Conditions: Glycogen Storage Disease IIIA

Summary: the investigators will study if acute nutritional ketosis in adult gsd iiia patients can boost muscle mitochondrial function in vivo.

glycogen storage disease type iiia (gsd iiia) is an inborn error of carbohydrate metabolism caused by impaired glycogen debranching enzyme (gde) activity. the ageing gsd iiia cohort shows that muscle involvement -despite dietary management- is a common disabling phenotype in adulthood. currently, no specific therapy has been established for muscle problems in adult gsd iiia patients. however, it could be hypothesized that nutritional ketosis (nk) will be highly beneficial to patients. amongst others, ketone bodies could take on the role of primary energy source in exercising muscle. recently, acute nk in exercise was studied in humans. nk was found to enhance muscle mitochondrial function in athletes. the investigators will study if acute nk in adult gsd iiia patients can boost muscle mitochondrial function in vivo.

Eligibility criteria:
inclusion criteria: * gsd iii confirmed with enzyme assay and/or agl mutation analysis and gsd iiia further specified as deficient debranching enzyme activity in muscle or clinical and/or biochemical signs of cardiac and/or skeletal muscular involvement. exclusion criteria: * contraindications for mri studies (assessed by standardised questionnaire) * inability to perform bicycle exercise. * intercurrent illness which may influence exercise tolerance (anemia, musculoskeletal injury, or other undiagnosed illness under investigation). * known coronary artery disease, positive history for angina or cardiomyopathy. * insulin-dependent diabetes mellitus. * loss of, or an inability to give informed consent. * pregnancy or current breastfeeding. * any other cause which in the opinion of the investigators, may affect the participant's ability to participate in the study

Keywords: glycogen storage disease type iiia exercise ketone esters magnetic resonance spectroscopy
3-year follow-up study to assess the viral activity in hepatitis c patients who failed feeder deb025/alisporivir study

Conditions: Hepatitis C, Chronic

Summary: follow-up for viral activity, changes in liver function and safety in patients with no svr24 in feeder studies

the purpose of this study was to follow patients from the feeder studies who have not achieved svr24 to assess their viral activity, and to assess the changes in liver function and disease, and post-treatment safety over time.

Eligibility criteria:
inclusion criteria: 1. males or females aged ≥18 2. have previously completed a novartis-sponsored hepatitis c study and received alisporivir or a direct antiviral agent (daa) 3. have not achieved svr24 exclusion criteria: 1. use of any investigational drugs within 5 half-lives of enrollment, or within 30 days of that medication, whichever is longer. 2. previous use of any course of hepatitis c therapy since the end of the novartis-sponsored hepatitis c study

Keywords: hepatitis c, chronic
a clinical trial of esophagectomy for esophageal carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: brief summary the pathological type of esophageal cancer (ec) in most patients in east asia is esophageal squamous cell carcinoma (escc). surgery is the primary treatment for ec. this study compared the feasibility and safety of mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (matle) with video-assisted thoracoscopic esophagectomy (vate). thirty-five eligible patients with escc were assigned to the matle group, while seventy matched patients were assigned to the vate group. the study compared perioperative outcomes and lymph node dissection between the two groups. additionally, the kaplan-meier method was employed to estimate disease-free survival (dfs) and overall survival (os).


Eligibility criteria:
inclusion criteria: * previously untreated * histologically confirmed * potentially resectable thoracic escc clinically staged as t1b-3n0m0 or tis-1an0m0 who was not suitable for endoscopic resection according to the 8th edition of the american joint committee on cancer staging system and national comprehensive cancer network clinical practice guidelines in esophageal and esophagogastric junction cancers * age 18-70 years, * normal hematologic and organ function -karnofsky performance scale (kps) was assessed as 100 or 90 exclusion criteria: * a history of other malignancies * severe comorbidities * active autoimmune disease * prior non-infectious pneumonitis or interstitial lung disease
investigations of amygdala function using neurophysiological recording and stimulation

Conditions: Fear; PTSD; Panic Disorder

Summary: this study aims to specifically examine the in vivo electrophysiology and effects of direct stimulation of the human amygdala during conditioned and evoked fear. investigators will also examine amygdala electrophysiology and the effects of stimulation during tasks to examine the effects of reward on fear memory. this study will recruit subjects with a history of temporal lobe epilepsy (tle) who have undergone neurosurgical implantation with fda-approved, neuropace rns devices for treatment of seizures. these patients provide a unique cohort with (responsive neurostimulation) rns devices capable of both recording and stimulating the amygdala during performance of fear-based, behavioral tasks.


Eligibility criteria:
inclusion criteria: * be between age 18-65 years of age * participants must have received the neuropace rns implant to treat their seizures * have comprehension of instructions in the english language * be on a stable dose of medications for their epilepsy * have received the rns system for temporal lobe epilepsy * have capacity to provide informed consent exclusion criteria: * significant cognitive impairment (mini mental status examination score of less than 20) * dsm-v diagnosis of alcohol/substance abuse (except nicotine) within the last month or a diagnosis of alcohol/substance dependence (except nicotine) within the last 6 months * unable to apply eeg cap * history of traumatic brain injury * active or high suicide risk * unable to come to study site/lack of stable housing * is pregnant or nursing * patient's treating neurologist determines that the patient's epilepsy is not stable enough to participate in this study * any condition (including psychiatric) which in the judgment of the investigator would prevent the subject from completion of the study

Keywords: responsive neurostimulation amygdala electrophysiology neuropace rns temporal lobe epilepsy closed-loop brain stimulation
uk imaging diabetes study seeing diabetes clearly

Conditions: Type2 Diabetes

Summary: prospective, observational cohort study to cross-sectionally assess the health of multiple organs, using multiparametric abdominal magnetic resonance imaging (mri) scan, and understand if resulting mri metrics can predict future clinical events over a period of 5 years, in adult patients with type 2 diabetes lacking history of cardiovascular disease.

this will be a multi-site study adopting a prospective, observational cohort study design. there will be no intervention to the standard of care. study participants will be enrolled in this study for a total of 5 years, with only 1 month of active participation. participants will be required to attend a screening visit and 2 study visits. the screening visit will involve a medical review and receiving informed consent based on the participant information leaflet already communicated to the patient, pre-screening. the first study visit- baseline (visit 1) - will involve anthropometric measurements and taking a blood and urine sample in order to perform standard of care measurements for type 2 diabetes at baseline and relevant circulating biomarkers. the second study visit will involve having a multi-organ, multiparametric mri scan. both visits will be within 28 days of the screening visit and carried out at local study sites. mri metrics of organ health, clinical outcome measurements, blood samples and urine samples will be collected to assess the natural history of diabetes disease progression. participants will be asked to give consent for access to their medical records held at nhs england and, if available, at their local gp surgery or hospital. medical records access will include hospital admissions (hospital episode statistics), and mortality data collected by the office for national statistics and provided by nhs england to meet the primary objective. this data will be collected at 1, 3 and 5 years after baseline assessment.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age and diagnosed with type 2 diabetes, with or without diabetic retinopathy. * participant willing and able to give informed consent for participation in the study. exclusion criteria: in 12 months prior to consent, evidence of existing cardiovascular event defined as at least one of: * myocardial infarction * ischaemic stroke * hospital admission/discharge for unstable angina * heart surgery * unstable angina * transient ischemic attack * the participant may not enter the study if they have any contraindication to magnetic resonance imaging (standard mr exclusion criteria including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia). * patients with known autoimmune hepatitis, viral hepatitis, wilson's disease or known significant structural renal tract abnormality. * patients with known alcohol dependency. * any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the participant's ability to participate in the study
turkish edinburgh feeding evaluation in dementia (edfed) scale

Conditions: Dementia; Feeding Difficulties; Reliability and Validity

Summary: this study was conducted to evaluate the psychometric properties, including interobserver agreement, of the turkish version of the edinburgh feeding evaluation in dementia (edfed) scale, which was developed to assess eating difficulties in patients with dementia.

eating difficulties are common in dementia patients and can lead to malnutrition. early detection and intervention of these difficulties is of great importance to minimise the negative effects. therefore, a reliable and valid tool for assessing nutritional difficulties in dementia patients is needed.

Eligibility criteria:
inclusion criteria: * those over the age of 65, * those diagnosed with dementia, * patients who are able to weigh themselves (no lower extremity loss) exclusion criteria: • (cdr\<2)

Keywords: dementia edfed interobserver agreement
efficacy and safety study of medical thoracoscope cryotherapy combined standard first-line treatment of advanced non-small cell lung cancer and malignant pleural effusion

Conditions: Non Small Cell Lung Cancer

Summary: this study intends to investigate the efficacy and safety of medical thoracoscopic cryotherapy combined with standard first-line treatment of advanced non-small cell lung cancer with malignant pleural effusion through a randomized controlled clinical trial.


Eligibility criteria:
inclusion criteria: 1. 18-75 years old; 2. non-small cell lung cancer with pleural metastasis confirmed by histopathology or cytology; 3. ecog score 0-1; 4. cardiopulmonary function can tolerate painless thoracoscopic examination; 5. patients who underwent medical thoracoscopy for pleural effusion at first diagnosis and underwent medical thoracoscopy cryotherapy at the same time of biopsy were also included in the study. non-small cell lung cancer was confirmed by pathological results; 6. all subjects or their guardians must sign the informed consent before entering the study. exclusion criteria: 1. expected survival \<2 months; 2. hemoglobin \<110g/l, white blood cell count \<3×109/l, neutrophil \<2.0×109/l, platelet \<100×109/l; 3. severe cardiac insufficiency, abnormal liver and kidney function (blood test results of transaminase and creatinine \> 1.5 times the normal upper limit); 4. have received chemotherapy or anti-angiogenic drugs (such as bevacizumab, endu, anlotinib, etc.); 5. history of radiotherapy; 6. history of intrathoracic local treatment; 7. multiple serous cavity effusion, or bilateral pleural effusion; 8. patients allergic to erythromycin; 9. the lung cannot be reopened.

Keywords: advanced non-small cell lung cancer malignant pleural effusion thoracoscopy cryotherapy effect
fecal microbiota transplantation in agvhd after asct

Conditions: Graft Versus Host Disease in GI Tract

Summary: acute graft-versus-host-disease (agvhd) is a typical complication after allogeneic hematopoetic stem cell transplantation (asct). about 30-60% of patients after asct are affected by agvhd, which constitutes a relevant burden of morbidity and mortality in these patients. fecal microbiota transplantation (fmt) is a therapeutic concept to treat intestinal dysbiosis of various origin by infusion of the stool microbiota of a healthy donor into the gastrointestinal tract (gi) of a patient. fmt can be performed endoscopically by colonoscopic deployment of the donor microbiota into the patient´s caecum and terminal ileum. patients with gastrointestinal agvhd (gi-agvhd) are known to comprise a significant dysbiotic colonic microbiota that can be attenuated by fmt.


Eligibility criteria:
inclusion criteria: * first episode of histologically confirmed, steroid-refractory gi-agvhd * reduced bacterial diversity in the patient´s stool microbiota evidenced by 16s-rdna measurement * eligibility for repeated colonoscopic procedures * informed consent exclusion criteria: * complications during a previous colonoscopy * recurrent episode of gi-agvhd * lacking cardiopulmonary fitness for repeated colonoscopic procedures * septic infection * acute extraintestinal organ failure (excluding bone marrow) * mechanical ileus
functional brain imaging of medication treatment response in mild alzheimer's disease patients

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to determine whether standard medications approved for alzheimer's disease treatment differ in their action on brain functioning and whether any observed brain activity differences as result of treatment are associated with particular patterns of dementia improvement or reduced decline.

this study seeks to differentiate task-related and resting brain activity patterns captured via functional magnetic resonance imaging (fmri) and associated with two common alzheimer's disease (ad) medications, equivalent in acetylcholinesterase inhibition effect (achei) but differing with respect to allosteric nicotinic receptor modulation effect. it is the primary aim of this project to gain a better understanding of the brain mechanisms involved in the attentional and executive skills improvements associated with nicotinic receptor modulation in mild ad patients. to address this question, this 12-week continuous treatment, double-blind, head-to-head dose-escalation treatment trial seeks to visualize any treatment response unique to allosteric nicotinic receptor modulation and to associate these fmri data with standard cognitive assessment outcomes. using in-scanner tasks shown to reliably elicit brain activity in cortical regions important to memory and attention, this treatment trial will examine both resting and task-related bold signal characteristics in a well-characterized sample of 36 mild ad patients after periods of low dose and high dose ad dementia treatment with either galantamine hydrobromide (achei + nicotinic receptor modulation) or donepezil hydrochloride (achei only). both the low and high dose imaging comparisons between treatment groups will be equivalent for 35% achei-effect, which may allow for the isolation of bold signal unique to allosteric nicotinic receptor modulation in both brain at rest and task-related brain states.

Eligibility criteria:
inclusion criteria: * must meet diagnosis of mild alzheimer's disease * must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study * if female, must be post-menopausal * must be able to swallow tablets exclusion criteria: * metal implants or medical devises unsafe for mri use * pre-menopausal female * history of recent head injury * significant major, life-threatening illness or injury (e.g., stroke, aids, etc.) * vascular dementia or any dementia other than alzheimer's disease * history of significant alcoholism or drug abuse * history of seizure disorder, developmental delay or major psychiatric illness

Keywords: alzheimer's disease fmri functional neuroimaging allosteric nicotinic receptor modulation acetylcholinesterase inhibition head to head dose escalation biomarker